MCID: DDN001
MIFTS: 54

Duodenal Ulcer

Categories: Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Duodenal Ulcer

Summaries for Duodenal Ulcer

MalaCards based summary: Duodenal Ulcer, also known as stress ulcer, is related to gastric ulcer and pyloric stenosis. An important gene associated with Duodenal Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Signal Transduction and MIF Mediated Glucocorticoid Regulation. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and small intestine, and related phenotypes are nervous system and homeostasis/metabolism

Related Diseases for Duodenal Ulcer

Diseases in the Duodenal Ulcer family:

Duodenal Ulcer Due to Antral G-Cell Hyperfunction

Diseases related to Duodenal Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1065)
# Related Disease Score Top Affiliating Genes
1 gastric ulcer 31.6 SST S100A8 IL6 HRH2 GAST CYP2C19
2 pyloric stenosis 31.3 SST MLN GAST
3 peptic ulcer perforation 31.2 S100A8 HRH2 GAST
4 cholecystitis 31.0 TLR4 S100A8 CCK
5 active peptic ulcer disease 31.0 SST HRH2 CYP2C19
6 duodenitis 30.9 TNF SST S100A8 INS GAST CCK
7 atrophic gastritis 30.8 SST SCT S100A8 IL1RN IL1B GAST
8 cholelithiasis 30.8 SST INS GAST CCK
9 pernicious anemia 30.8 SST INS GAST
10 opisthorchiasis 30.8 TNF IL1B CXCL8
11 hypoglycemia 30.7 SST SCT INS GAST
12 bile reflux 30.7 S100A8 GAST CCK
13 intestinal obstruction 30.7 TNF MLN IL6
14 zollinger-ellison syndrome 30.7 SST SCT MLN HRH2 GRP GAST
15 duodenogastric reflux 30.6 SST SCT MLN GAST CCK
16 duodenum cancer 30.6 SST SCT GAST
17 varicose veins 30.6 TNF IL6 CXCL8
18 common cold 30.6 TNF IL6 IL1B IL10 CXCL8
19 peritonitis 30.6 TNF TLR4 IL6 IL1B IL10 CXCL8
20 gastrointestinal system disease 30.6 S100A8 MLN GAST CCK
21 dumping syndrome 30.5 SST SCT MLN INS GAST CCK
22 hernia, hiatus 30.5 MLN INS HRH2 GAST CYP2C19
23 pulmonary tuberculosis 30.5 TNF TLR4 IL6 IL1B IL10
24 neurotic disorder 30.5 TNF INS IL6 IL1B
25 esophagitis 30.4 TNF MLN IL6 IL1B IL10 HRH2
26 inflammatory bowel disease 1 30.4 TNF TLR4 IL6 IL1B IL10
27 peptic esophagitis 30.4 TNF S100A8 MLN IL6 IL1B HRH2
28 purpura 30.4 TNF IL6 IL1B IL10 CXCL8
29 duodenum disease 30.4 SST SCT S100A8 GAST
30 appendicitis 30.4 TNF TLR4 S100A8 IL6 IL1B IL10
31 human cytomegalovirus infection 30.4 TNF IL6 IL10
32 exanthem 30.3 TNF IL6 IL1B IL10 CXCL8
33 paine syndrome 30.3 TNF IL6 IL1B IL10 CXCL8
34 haemophilus influenzae 30.3 TNF IL1B CXCL8
35 bronchopneumonia 30.3 TNF IL6 IL1B IL10 CXCL8
36 ileus 30.3 TNF IL6 IL1B IL10 CXCL1
37 cholangitis 30.3 TNF TLR4 SST IL6 IL10 CXCL8
38 gastrinoma 30.3 SST SCT INS GRP GAST
39 lymphoma, mucosa-associated lymphoid type 30.3 TLR4 S100A8 GAST CXCL8
40 achalasia 30.3 TNF LTA IL10 GRP GAST
41 gastroparesis 30.3 SST SCT MLN HRH2 GAST CCK
42 intestinal perforation 30.2 TNF IL6 IL10
43 alcohol use disorder 30.2 TNF TLR4 INS IL6 IL1B
44 food allergy 30.2 TNF IL10 CXCL8
45 angina pectoris 30.2 TNF INS IL6
46 liver cirrhosis 30.2 TNF SST SCT INS IL6
47 pneumonia 30.2 TNF TLR4 IL6 IL1B IL10 CXCL8
48 peptic ulcer disease 30.2 TNF SST SCT S100A8 INS IL6
49 biliary dyskinesia 30.2 SST SCT CCK
50 vasculitis 30.2 TNF IL6 IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Duodenal Ulcer:



Diseases related to Duodenal Ulcer

Symptoms & Phenotypes for Duodenal Ulcer

GenomeRNAi Phenotypes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.11 CCK CXCL1 CXCL8 CYP2C19 GAST GRP
2 no effect GR00402-S-2 10.11 CCK CYP2C19 GAST HRH2 IL10 IL1B

MGI Mouse Phenotypes related to Duodenal Ulcer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 CCK GRP HRH2 IL10 IL1B IL6
2 homeostasis/metabolism MP:0005376 10.1 CCK CXCL1 GAST HRH2 IL10 IL1B
3 neoplasm MP:0002006 9.91 GAST IL10 IL1B IL6 PSCA TLR4
4 digestive/alimentary MP:0005381 9.76 GAST HRH2 IL10 IL6 INS SST
5 immune system MP:0005387 9.73 CXCL1 GAST IL10 IL1B IL1RN IL6
6 skeleton MP:0005390 9.32 CXCL1 IL10 IL1B IL1RN IL6 INS

Drugs & Therapeutics for Duodenal Ulcer

Drugs for Duodenal Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
5
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
6
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Ranitidine Approved, Withdrawn Phase 4 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
9
Sucralfate Approved Phase 4 54182-58-0
10
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
11
Famotidine Approved Phase 4 76824-35-6 3325 5702160
12
Histamine Approved, Investigational Phase 4 51-45-6 774
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714
15 Bismuth tripotassium dicitrate Phase 4
16
Bismuth Phase 4 7440-69-9 105143
17 Citrate Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Anti-Bacterial Agents Phase 4
20 Anti-Infective Agents Phase 4
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Expectorants Phase 4
24 Antimalarials Phase 4
25 Respiratory System Agents Phase 4
26 Anti-Infective Agents, Local Phase 4
27 Monoamine Oxidase Inhibitors Phase 4
28 diuretics Phase 4
29
Ranitidine bismuth citrate Phase 4
30 Anti-Ulcer Agents Phase 4
31 Antacids Phase 4
32 Proton Pump Inhibitors Phase 4
33 Gastrointestinal Agents Phase 4
34 Neurotransmitter Agents Phase 4
35
Histamine phosphate Phase 4 51-74-1 134614
36 Histamine H2 Antagonists Phase 4
37 Histamine Antagonists Phase 4
38
Clarithromycin Approved Phase 3 81103-11-9 84029
39
Metronidazole Approved Phase 2, Phase 3 443-48-1, 69198-10-3 4173
40
Rabeprazole Approved, Investigational Phase 2, Phase 3 117976-89-3, 117976-90-6 5029
41
Rebamipide Approved, Investigational Phase 2, Phase 3 90098-04-7 5042
42
Cimetidine Approved, Investigational Phase 3 51481-61-9 2756
43
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
44
Acetylsalicylic acid Approved, Vet_approved Phase 3 50-78-2 2244
45
Gefarnate Investigational Phase 3 51-77-4 3459
46 Cytochrome P-450 CYP3A Inhibitors Phase 3
47 Analgesics Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 3
49 Antirheumatic Agents Phase 3
50 Cyclooxygenase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Completed NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
3 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin
4 Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit Completed NCT00633035 Phase 4 esomeprazole 40 mg;famotidine 20 mg
5 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
6 Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial Completed NCT00708149 Phase 4 lansoprazole OD;placebo
7 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
8 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
9 Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
10 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Completed NCT03667703 Phase 4 Famotidine;Placebo
11 Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study. Completed NCT00590928 Phase 4 esomeprazole;ranitidine
12 Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery Terminated NCT00839488 Phase 4 pantoprazole 40 mg iv;famotidine 20 mg iv
13 A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers. Unknown status NCT04215653 Phase 3 Anaprazole Sodium;Rabeprazole;Rabeprazole Placebo;Anaprazole Sodium Placebo
14 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
15 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
16 A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection Completed NCT03050359 Phase 3 TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
17 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China Completed NCT00952978 Phase 3 10 mg ilaprazole;20 mg omeprazole
18 A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer Completed NCT01452724 Phase 3 TAK-438;Placebo;Lansoprazole
19 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China Completed NCT02847455 Phase 2, Phase 3 5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
20 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
21 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
22 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
23 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo
24 A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA) Completed NCT00441727 Phase 3 Esomeprazole 40 mg;Esomeprazole 20 mg;Placebo
25 High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment Completed NCT00132171 Phase 3 Sequential therapy
26 A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00595517 Phase 3 Esomeprazole 20 mg
27 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
28 Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study Completed NCT02166008 Phase 2, Phase 3 Repamipide;Placebo
29 A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use Completed NCT01069939 Phase 3 Esomeprazole;Placebo
30 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;Lansoprazole
31 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID). Completed NCT01452750 Phase 3 TAK-438;Placebo;Lansoprazole
32 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;Lansoprazole
33 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;Lansoprazole
34 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole
35 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial- Completed NCT01397448 Phase 2, Phase 3 E3810;Teprenone
36 Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study Completed NCT02157376 Phase 3 Esomeprazole;Cimetidine
37 Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU Completed NCT02290327 Phase 3 Pantoprazole;Placebo
38 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Placebo
39 Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
40 A Multi-center, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Compared to Lansoprazole in the Treatment of Duodenal Ulcer in Chinese Patients for up to 6 Weeks Recruiting NCT05010954 Phase 3 LXI-15028 50mg group;Lansoprazole 30mg group
41 An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin Active, not recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
42 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin. Terminated NCT00762359 Phase 3 Lansoprazole;Gefarnate
43 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China Completed NCT00953381 Phase 2 5 mg ilaprazole;10 mg ilaprazole;20 mg ilaprazole;20 mg omeprazole
44 MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) Completed NCT00543868 Phase 2 MK0782
45 A Phase 2,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. Completed NCT04503629 Phase 2 Anaprazole Sodium;Rabeprazole sodium
46 An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects Completed NCT01964131 Phase 1 D961H sachet 20 mg;D961H HPMC capsule 20 mg
47 Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Completed NCT00284908 Phase 1 S-Tenatoprazole-Na (STU-Na)
48 An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fasting Conditions Completed NCT01847404 Phase 1 Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one;Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two;ASA 100 mg tablet;Pantoprazole 20 mg gastro-resistant tablet
49 An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fed Conditions Completed NCT01847417 Phase 1 Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one;Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two;ASA 100 mg tablet;Pantoprazole 20 mg gastro-resistant tablet
50 Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding Unknown status NCT02108756 L-pantoprazole sodium;Panmeilu

Search NIH Clinical Center for Duodenal Ulcer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
lansoprazole
magaldrate
Magnesium Hydroxide
Maprotiline
Maprotiline Hydrochloride
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Prazepam
rabeprazole
Sucralfate

Cochrane evidence based reviews: duodenal ulcer

Genetic Tests for Duodenal Ulcer

Anatomical Context for Duodenal Ulcer

Organs/tissues related to Duodenal Ulcer:

MalaCards : Liver, Heart, Small Intestine, Pancreas, Adrenal Cortex, Colon, Lymph Node

Publications for Duodenal Ulcer

Articles related to Duodenal Ulcer:

(show top 50) (show all 21274)
# Title Authors PMID Year
1
Associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease in Chinese Han population. 53 62
19804405 2010
2
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 53 62
19930551 2009
3
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 53 62
19710266 2009
4
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. 53 62
19318661 2009
5
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 53 62
19399945 2009
6
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 53 62
18612816 2009
7
The prevalence of the duodenal ulcer promoting gene (dupA) in Helicobacter pylori isolates varies by ethnic group and is not universally associated with disease development: a case-control study. 53 62
19338650 2009
8
Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. 53 62
19040660 2009
9
The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. 53 62
19260336 2008
10
Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. 53 62
18809506 2008
11
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 53 62
18179773 2008
12
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. 53 62
18376130 2008
13
Effects of Helicobacter pylori Infection on gastric mucin expression. 53 62
18097286 2008
14
Helicobacter pylori environmental interactions: effect of acidic conditions on H. pylori-induced gastric mucosal interleukin-8 production. 53 62
17517062 2007
15
Stress ulcer prophylaxis in hospitalized patients not in intensive care units. 53 62
17592004 2007
16
Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. 53 62
17309748 2007
17
Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. 53 62
17539287 2007
18
Association between interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric carcinogenesis in a Chinese population. 53 62
17295877 2007
19
The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. 53 62
17044024 2007
20
Analysis of serum antibody profile against H pylori VacA and CagA antigens in Turkish patients with duodenal ulcer. 53 62
17106939 2006
21
[Expression of gastrin, somatostatin, PCNA and Fas-L in the mucosa of gastric antrum of children with chronic gastritis and duodenal ulcer]. 53 62
17229384 2006
22
Detection of Helicobacter pylori cagA gene in gastric biopsies, clinical isolates and faeces. 53 62
16912439 2006
23
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 53 62
16868800 2006
24
Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. 53 62
16550552 2006
25
Assay of gastrin and somatostatin in gastric antrum tissues of children with chronic gastritis and duodenal ulcer. 53 62
16610039 2006
26
Development of a novel method to detect Helicobacter pylori cagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. 53 62
16543737 2006
27
[The part of the hormone-cyclase system in achieving the therapeutic effect of hydrochloric acid secretion inhibitors at the duodenal ulcer]. 53 62
16866262 2006
28
IL1RN polymorphism and cagA-positive Helicobacter pylori strains increase the risk of duodenal ulcer in children. 53 62
16183821 2005
29
No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. 53 62
16164697 2005
30
[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. 53 62
16174594 2005
31
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. 53 62
16110845 2005
32
The humoral immuneresponse to Helicobacter pylori infection in children with gastrointestinal symptoms. 53 62
15866217 2005
33
Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. 53 62
15849833 2005
34
Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. 53 62
15762883 2005
35
Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. 53 62
15652446 2005
36
Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. 53 62
16325508 2005
37
[Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. 53 62
17378383 2005
38
Gastric epithelial anti-microbial peptides--histological correlation and influence of anatomical site and peptic ulcer disease. 53 62
15702860 2005
39
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 53 62
15627645 2004
40
TNF/LTA polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean population. 53 62
15381184 2004
41
High prevalence of multiple strain colonization of Helicobacter pylori in Korean patients: DNA diversity among clinical isolates from the gastric corpus, antrum and duodenum. 53 62
15053036 2004
42
The diversity of vacA and cagA genes of Helicobacter pylori in East Asia. 53 62
14734191 2004
43
Helicobacter pylori-induced immunological responses in patients with duodenal ulcer and in patients with cardiomyopathies. 53 62
15571071 2004
44
Lewis antigen expression in gastric mucosa of children: relationship with Helicobacter pylori infection. 53 62
14676601 2004
45
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. 53 62
14615467 2003
46
Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. 53 62
14632761 2003
47
[Effect of quamatel on neutrophil properties, parameters of lipid peroxidation and the antioxidant defense system in blood of patients with duodenal ulcer and pancreatitis]. 53 62
14743716 2003
48
History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. 53 62
14567455 2003
49
Local and peripheral cytokine response and CagA status of Helicobacter pylori-positive patients with duodenal ulcer. 53 62
14656687 2003
50
DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh. 53 62
12734242 2003

Variations for Duodenal Ulcer

Expression for Duodenal Ulcer

Search GEO for disease gene expression data for Duodenal Ulcer.

Pathways for Duodenal Ulcer

Pathways related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1 13.74 CCK CXCL1 CXCL8 GAST GRP HRH2
2
Show member pathways
13.65 CXCL1 CXCL8 IL10 IL1B IL1RN IL6
3
Show member pathways
13.61 SST SCT MLN HRH2 GRP GAST
4
Show member pathways
13.44 CXCL1 CXCL8 IL10 IL1B IL6 LTA
5
Show member pathways
13.41 SST SCT MLN HRH2 GRP CXCL8
6
Show member pathways
13.35 TNF LTA IL6 IL1RN IL1B IL10
7
Show member pathways
13.32 TNF LTA IL6 IL1B IL10 CXCL8
8
Show member pathways
12.85 TNF TLR4 IL6 IL1B CXCL8
9
Show member pathways
12.73 IL1B IL6 LTA TLR4 TNF
10 12.71 INS IL6 IL1B IL10 CXCL1
11
Show member pathways
12.67 TNF LTA IL6 IL1B IL10 CXCL8
12
Show member pathways
12.65 TNF IL6 IL1RN IL1B CXCL8
13
Show member pathways
12.62 TNF IL6 IL1B IL10 CXCL1
14
Show member pathways
12.56 TNF TLR4 IL6 IL1B CXCL8
15
Show member pathways
12.45 TNF TLR4 IL6 IL1RN IL1B CXCL8
16
Show member pathways
12.36 CXCL8 IL1B IL6 TLR4 TNF
17
Show member pathways
12.3 TNF IL6 CXCL8 CXCL1
18 12.14 IL10 IL1B IL6 LTA TNF
19 12.01 TNF TLR4 IL6 IL1B CXCL8 CXCL1
20 12 TNF IL6 IL1B IL10 CXCL8
21 11.98 INS IL6 IL1B CXCL8 CXCL1
22
Show member pathways
11.93 TLR4 IL6 CXCL8 CXCL1
23
Show member pathways
11.93 TNF TLR4 LTA IL6 IL1B IL10
24 11.92 TNF IL1B IL10 CXCL8
25 11.9 TNF SST IL6 IL1RN IL1B IL10
26
Show member pathways
11.86 TLR4 IL6 IL1B
27 11.85 TNF LTA IL1B IL10
28 11.81 TNF IL6 IL1B IL10
29
Show member pathways
11.8 TNF LTA IL1B
30 11.79 TNF TLR4 IL6 IL10
31 11.77 TLR4 IL6 IL10
32 11.73 IL6 IL10 CXCL8
33
Show member pathways
11.73 TNF IL6 IL1B CXCL8
34 11.72 TNF IL6 IL1B CXCL8
35
Show member pathways
11.69 IL10 IL6 TLR4 TNF
36 11.69 TNF TLR4 IL6 IL10 CXCL8
37 11.67 TNF TLR4 IL6 IL1B CXCL8 CXCL1
38 11.65 INS IL6 CXCL8
39 11.62 TNF TLR4 LTA
40 11.61 TNF IL10 CXCL8 CXCL1
41 11.61 TNF TLR4 IL6 CXCL8
42 11.56 TNF TLR4 IL1B
43 11.54 TNF INS IL6
44 11.53 TNF IL6 IL1B
45 11.5 TNF TLR4 IL6
46 11.37 TNF TLR4 IL6 IL1B IL10
47 11.36 TNF IL6 IL1B
48 11.31 TNF IL6 IL1B CXCL8
49 11.3 TNF IL1B CXCL1
50 11.26 TNF IL6 IL1B IL10 CXCL1

GO Terms for Duodenal Ulcer

Cellular components related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.13 CCK CXCL1 CXCL8 GAST GRP IL10
2 extracellular region GO:0005576 9.83 CCK CXCL1 CXCL8 GAST GRP IL10

Biological processes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.31 CXCL1 CXCL8 IL10 IL1B IL6 SST
2 inflammatory response GO:0006954 10.27 CXCL1 CXCL8 IL1B IL1RN IL6 S100A8
3 defense response to Gram-positive bacterium GO:0050830 10.26 TNF LTA IL6 IL1B
4 positive regulation of DNA-binding transcription factor activity GO:0051091 10.26 TNF IL6 IL1B IL10
5 positive regulation of inflammatory response GO:0050729 10.24 IL1B S100A8 TLR4 TNF
6 positive regulation of interleukin-6 production GO:0032755 10.23 TNF TLR4 IL6 IL1B
7 neutrophil chemotaxis GO:0030593 10.21 CXCL1 CXCL8 IL1B S100A8
8 positive regulation of type II interferon production GO:0032729 10.19 TNF TLR4 LTA IL1B
9 regulation of insulin secretion GO:0050796 10.16 TNF IL6 IL1B
10 response to activity GO:0014823 10.16 TNF IL6 IL10
11 positive regulation of nitric oxide biosynthetic process GO:0045429 10.15 TNF TLR4 IL1B
12 positive regulation of interleukin-8 production GO:0032757 10.15 TNF TLR4 IL6 IL1B
13 lipopolysaccharide-mediated signaling pathway GO:0031663 10.14 TNF TLR4 IL1B
14 response to glucocorticoid GO:0051384 10.14 TNF IL6 IL1RN IL10
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.14 TNF TLR4 S100A8 INS IL6 IL1B
16 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.13 TNF IL6 IL10
17 positive regulation of cytokine production GO:0001819 10.12 TNF INS IL1B IL10
18 positive regulation of mitotic nuclear division GO:0045840 10.11 TNF INS IL1B
19 liver regeneration GO:0097421 10.1 IL10 IL6 TNF
20 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.09 TNF TLR4 IL6
21 negative regulation of neurogenesis GO:0050768 10.09 TNF IL6 IL1B
22 negative regulation of lipid catabolic process GO:0050995 10.04 TNF INS IL1B
23 embryonic digestive tract development GO:0048566 10.03 CXCL8 SCT TNF
24 positive regulation of chemokine production GO:0032722 10.02 TNF TLR4 IL6 IL1B
25 response to lipopolysaccharide GO:0032496 10.02 TNF TLR4 S100A8 LTA IL1B IL10
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 10 TNF IL1B IL10
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.98 IL6 IL1RN
28 positive regulation of oxidative stress-induced neuron death GO:1903223 9.98 TNF TLR4
29 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.98 TNF LTA
30 negative regulation of cytokine production involved in immune response GO:0002719 9.97 TNF IL10
31 positive regulation of fever generation GO:0031622 9.97 IL1B TNF
32 cellular response to lipopolysaccharide GO:0071222 9.97 TNF TLR4 IL6 IL1B IL10 CXCL8
33 sequestering of triglyceride GO:0030730 9.95 TNF IL1B
34 positive regulation of neuroinflammatory response GO:0150078 9.93 TNF IL6 IL1B
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.92 TNF IL1B
36 vascular endothelial growth factor production GO:0010573 9.91 IL1B IL6 TNF
37 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.9 TNF LTA
38 chronic inflammatory response to antigenic stimulus GO:0002439 9.89 TNF IL10
39 positive regulation of glial cell proliferation GO:0060252 9.86 IL1B IL6 LTA TNF
40 immune response GO:0006955 9.8 CXCL1 CXCL8 HRH2 IL10 IL1B IL1RN
41 signal transduction GO:0007165 9.75 TNF TLR4 SCT MLN LTA INS
42 response to external stimulus GO:0009605 9.69 TLR4 CXCL8 CXCL1

Molecular functions related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.93 TNF TLR4 SCT LTA IL6 GRP
2 hormone activity GO:0005179 9.73 SST SCT MLN INS GAST CCK
3 cytokine activity GO:0005125 9.47 TNF LTA IL6 IL1RN IL1B IL10

Sources for Duodenal Ulcer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....